Vanda Pharmaceuticals, Inc. (VNDA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Soleno Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Phibro Animal Health Corp.

Ovid Therapeutics, Inc.

Vanda Pharmaceuticals, Inc.

Compass Therapeutics, Inc.

Atea Pharmaceuticals, Inc.

Inozyme Pharma, Inc.

Third Harmonic Bio, Inc.

Fulcrum Therapeutics, Inc.

Acumen Pharmaceuticals, Inc.

Why is Vanda Pharmaceuticals, Inc. ?

Poor long term growth as Net Sales has grown by an annual rate of -2.73% over the last 5 years

The company has declared negative results for the last 12 consecutive quarters

NET PROFIT(HY) At USD -189.75 MM has Grown at -451.51%
OPERATING CASH FLOW(Y) Lowest at USD -126.52 MM
ROCE(HY) Lowest at -60.48%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 28.04%, its profits have fallen by -1066.5%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Vanda Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Vanda Pharmaceuticals, Inc.

33.04%

-0.04

79.17%

S&P 500

25.22%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-2.73%

EBIT Growth (5y)

-240.88%

EBIT to Interest (avg)

-3.96

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.66

Sales to Capital Employed (avg)

0.40

Tax Ratio

20.45%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

91.78%

ROCE (avg)

23.96%

ROE (avg)

2.66%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.25

EV to EBIT

-0.99

EV to EBITDA

-1.08

EV to Capital Employed

2.18

EV to Sales

0.69

PEG Ratio

Dividend Yield

ROCE (Latest)

-219.75%

ROE (Latest)

-67.38%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -0.67% (YoY

-22What is not working for the Company

NET PROFIT(HY)

At USD -189.75 MM has Grown at -451.51%

OPERATING CASH FLOW(Y)

Lowest at USD -126.52 MM

ROCE(HY)

Lowest at -60.48%

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.29 times

CASH AND EQV(HY)

Lowest at USD 466.26 MM

OPERATING PROFIT(Q)

Lowest at USD -46.7 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -90.29 %

PRE-TAX PROFIT(Q)

Lowest at USD -48.42 MM

Here's what is working for Vanda Pharmaceuticals, Inc.

Raw Material Cost

Fallen by -0.67% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Vanda Pharmaceuticals, Inc.

Net Profit

At USD -189.75 MM has Grown at -451.51%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Pre-Tax Profit

At USD -48.42 MM has Fallen at -39.7%

over average net sales of the previous four periods of USD -34.66 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Operating Cash Flow

Lowest at USD -126.52 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Debtors Turnover Ratio

Lowest at 4.29 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Operating Profit

Lowest at USD -46.7 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at -90.29 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at USD -48.42 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Cash and Eqv

Lowest at USD 466.26 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents